Evonik Industries Licenses ERGO™ Genomics Platform for Specialty Chemicals Optimization Research Using Microbial Genomes

Integrated Genomics, Inc. has licensed the ERGO™ genomics platform for use in research and production systems to Evonik Industries.

Under the terms of the agreement, scientists of the Evonik Science-to-Business Center Biotechnology will use the ERGO™ system to optimize their production strains and find new methods for high yield production of specialty chemicals.

Integrated Genomics ERGO™ platform is the leading genomic tool for microbial systems biology.

“We have found the ERGO™ discovery system to be an exceptionally useful tool for our metabolic engineering projects and expect that it will assist us in developing new production strains for higher and more cost effective production of biological compounds ”, said Dr. Thomas Haas, Director Science-to-Business Center Biotechnology at Evonik.

Optimized for analysis of microorganisms, ERGO™ integrates biological data from genomics, biochemistry, gene expression studies, genetics and literature.

Reaching beyond conventional systems for functional analysis by DNA sequence alone, Integrated Genomics' platform combines pattern-based analyses with a repertoire of comparative genomics tools for gene visualization in the contexts of regulation, expression data, phylogeny, chromosomal neighborhoods and gene fusions. ERGO™ contains more than 1500 genomes at various stages of completion, as well as the largest available collection of networked cellular pathways.